Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA Million Veteran Program analysis of 431,107 participants identified two independent variants at the GLP-1 receptor locus that each raise body mass index. After adjusting for BMI, one variant retains its association with type 2 diabetes (BMI-independent pathway) while the other fully attenuates (BMI-mediated pathway). The result refines the genetic architecture at this drug-class target.
A new Bayesian meta-analysis in Neurology pooled five observational studies covering 1,593,554 patients and put the semaglutide NAION risk at relative risk 2.52 (95% credible interval 1.56-4.72), with 118 cases per 100,000 semaglutide users. The result quantifies the safety signal flagged in yesterday's GLP-1 ocular review piece.
A Nature paper from DiMarchi, Tschöp, and colleagues describes a unimolecular conjugate combining a GLP-1R/GIPR co-agonist peptide with the pan-PPAR agonist lanifibranor through a pH-sensitive linker. After receptor internalization, the linker cleaves and the small-molecule payload escapes to the nucleus while the peptide continues signaling at the membrane. In obese diabetic mice, the conjugate outperformed peptide alone.
A 2026 narrative review in J Obes Metab Syndr consolidates the GLP-1 ocular picture: transient early diabetic retinopathy worsening is real but driven by metabolic transition, age-related macular degeneration and glaucoma show protective signals, and a new NAION safety signal has emerged in specific cohorts. A 2025 multidisciplinary consensus replaces avoidance with risk-stratified monitoring.
A retrospective cohort in Plastic and Reconstructive Surgery analyzed 552 abdominal body contouring patients between 2013 and 2025. Combined bariatric + GLP-1 weight loss predicted seroma (OR 3.05), hematoma (OR 3.74), and unplanned return to the operating room (OR 6.78), independent of total weight lost.
A 16-week double-blind randomized trial in JAMA Psychiatry reports that semaglutide significantly improved effort-based decision-making in patients with major depressive disorder. Computational modeling showed the effect was driven by reduced effort discounting, with sensitivity to reward probability unchanged. First RCT evidence that GLP-1 drugs touch the reward circuitry in clinical depression.
A target-trial emulation in 333,687 Veterans Affairs patients found similar all-cause acute pancreatitis rates between GLP-1 and sulfonylurea users at one year. But drug-induced pancreatitis was up early in the GLP-1 arm, while hypertriglyceridemia and alcohol-related pancreatitis were down later. Net increased risk concentrates in the first two to three months.
An American Journal of Sports Medicine review surveys BPC-157, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu, the injectable peptides driving sports-medicine patient demand. The review's verdict is that preclinical evidence is real, human evidence is essentially absent, and the orthopedic community wants research infrastructure paired with any access decision the FDA makes in July.
A mouse study in Neuropharmacology mapped GLP-1 receptors across the cerebellum using four methods and found them in granule cells, mossy fibers, and the deep cerebellar nuclei. The cerebellum projects to the brain's reward circuit, suggesting a new piece of why Wegovy-class drugs work.
Mutant p53 has resisted small-molecule drug development for decades. A new mouse study uses an intranasal peptide vaccine instead, and reports smaller tumors, longer survival, and stronger T-cell infiltration in vaccinated animals carrying a Trp53 R270H mutation.
An Endocrine Reviews paper argues that GLP-1 and orexin, two peptide systems usually treated separately, are dysregulated together in long COVID and chronic fatigue. The therapeutic implication: combine GLP-1 drugs with orexin-targeting medication.
A 173,216-patient cohort with type 2 diabetes and pre-existing diabetic retinopathy showed GLP-1 users had lower progression to proliferative retinopathy (HR 0.78), retinal vein occlusion (HR 0.70), and neovascular glaucoma (HR 0.65). NAION risk was null (HR 0.88, CI 0.54-1.44).
Boehringer Ingelheim's Phase 3 SYNCHRONIZE-1 trial cleared its 76-week primary endpoint visit, with topline expected H1 2026. Survodutide is a GLP-1/glucagon dual agonist co-developed with Zealand Pharma, positioning to enter the obesity drug market behind semaglutide and tirzepatide.
Crinetics Pharmaceuticals' CRN09682 entered Phase 1/2 BRAVESST2 trials this month. It pairs a small-molecule SST2 agonist with monomethyl auristatin E and targets the same receptor as Lutathera and Perspective Therapeutics' alpha-PRRT, trading peptide selectivity for small-molecule manufacturing simplicity.
A Heart Rhythm cohort of 12,812 patients found GLP-1 therapy reduced atrial fibrillation incidence (HR 0.67) and mortality (HR 0.34) versus matched controls. The protective effect persisted in patients who gained weight on therapy. Only semaglutide reached statistical significance, and the AF benefit took two years to appear.